within Pharmacolibrary.Drugs.ATC.R;

model R06AE09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 1.0500000000000001e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.017166666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AE09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Levocetirizine is a selective, non-sedating antihistamine used primarily for the symptomatic relief of allergic rhinitis (including hay fever) and chronic idiopathic urticaria. It is the levo-enantiomer of cetirizine and is available as an approved medication in many countries for both adults and children.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following oral administration of a single 5 mg dose.</p><h4>References</h4><ol><li><p>Ino, H, et al., &amp; Fukase, H (2014). Comparison of levocetirizine pharmacokinetics after single doses of levocetirizine oral solution and cetirizine dry syrup in healthy Japanese male subjects. <i>Journal of drug assessment</i> 3(1) 38–42. DOI:<a href=\"https://doi.org/10.3109/21556660.2014.928302\">10.3109/21556660.2014.928302</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27536452/\">https://pubmed.ncbi.nlm.nih.gov/27536452</a></p></li><li><p>Moon, SJ, et al., &amp; Kim, MG (2020). Comparative pharmacokinetics of a montelukast/levocetirizine fixed-dose combination chewable tablet versus individual administration of montelukast and levocetirizine after a single oral administration in healthy Korean male subjects . <i>International journal of clinical pharmacology and therapeutics</i> 58(6) 354–362. DOI:<a href=\"https://doi.org/10.5414/CP203709\">10.5414/CP203709</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32271144/\">https://pubmed.ncbi.nlm.nih.gov/32271144</a></p></li><li><p>Ino, H, et al., &amp; Nakano, A (2020). Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese Volunteers. <i>Clinical pharmacology in drug development</i> 9(7) 805–812. DOI:<a href=\"https://doi.org/10.1002/cpdd.791\">10.1002/cpdd.791</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32196954/\">https://pubmed.ncbi.nlm.nih.gov/32196954</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AE09;
